Originally published by our sister publication Infectious Disease Special Edition
By IDSE News Staff
The American Academy of Pediatrics (AAP) urged federal leaders who oversee the immunizations of U.S. children to rapidly implement the changes that will be needed to ensure all children can access nirsevimab (Beyfortus, AstraZeneca), for respiratory syncytial virus (RSV).
The Advisory Committee on Immunization Practices and the CDC recently recommended universal distribution of nirsevimab to reduce